Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3651
Rallybio
RLYB
$88.1M
| $91K | ﹤0.01% |
+1,725
| New | +$102K |
|
|
ATIP
3652
DELISTED
ATI Physical Therapy, Inc.
ATIP
| $91K | ﹤0.01% |
5,952
+874
| +17% | +$29.5K |
|
3653
Oriental Culture Holding
OCG
$3.24M
| $90K | ﹤0.01% |
54
-21
| -28% | -$44.9K |
|
3654
Capricor Therapeutics
CAPR
$244M
| $89K | ﹤0.01% |
23,021
+12,821
| +126% | +$61.2K |
|
3655
ReTo Eco-Solutions
RETO
$10.2M
| $89K | ﹤0.01% |
1
| – | – |
|
|
AUTL
3656
Autolus Therapeutics
AUTL
$564M
| $88K | ﹤0.01% |
46,300
+21,100
| +84% | +$53.4K |
|
3657
AEye
LIDR
$59.5M
| $88K | ﹤0.01% |
+6,130
| New | +$159K |
|
3658
Comstock
LODE
$265M
| $88K | ﹤0.01% |
32,021
+27,506
| +609% | +$100K |
|
|
SUPV
3659
Grupo Supervielle
SUPV
$725M
| $88K | ﹤0.01% |
+40,900
| New | +$75K |
|
|
EPIX
3660
DELISTED
ESSA Pharma
EPIX
| $87K | ﹤0.01% |
34,624
-151,286
| -81% | -$434K |
|
3661
Moleculin Biotech
MBRX
$4.06M
| $87K | ﹤0.01% |
219
-6
| -3% | -$2.53K |
|
|
RBOT
3662
DELISTED
Vicarious Surgical
RBOT
| $87K | ﹤0.01% |
+1,433
| New | +$133K |
|
|
VIOT
3663
Viomi Technology
VIOT
$48M
| $87K | ﹤0.01% |
81,264
-4,100
| -5% | -$3.93K |
|
|
WKEY
3664
WISeKey
WKEY
$82.2M
| $87K | ﹤0.01% |
19,620
-720
| -4% | -$2.93K |
|
|
MAAS
3665
Maase Inc
MAAS
$7.26B
| $87K | ﹤0.01% |
190
-69
| -27% | -$29.3K |
|
|
OKUR
3666
OnKure Therapeutics
OKUR
$159M
| $87K | ﹤0.01% |
3,720
-580
| -13% | -$15.4K |
|
|
RVPH
3667
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $86K | ﹤0.01% |
+1,015
| New | +$77.4K |
|
3668
Stagwell
STGW
$2.29B
| $86K | ﹤0.01% |
13,900
-61,400
| -82% | -$443K |
|
|
BIOC
3669
DELISTED
Biocept, Inc.
BIOC
| $86K | ﹤0.01% |
5,410
-203
| -4% | -$4.48K |
|
3670
NanoViricides
NNVC
$34.9M
| $85K | ﹤0.01% |
76,973
+5,907
| +8% | +$9.21K |
|
|
TMQ
3671
Trilogy Metals
TMQ
$650M
| $85K | ﹤0.01% |
154,758
-81,263
| -34% | -$47.4K |
|
|
SNCE
3672
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $85K | ﹤0.01% |
10,267
+5,252
| +105% | +$103K |
|
3673
EyePoint Inc
EYPT
$1.16B
| $84K | ﹤0.01% |
+24,000
| New | +$106K |
|
3674
Soluna Holdings
SLNH
$205M
| $84K | ﹤0.01% |
12,823
+6,667
| +108% | +$164K |
|
|
RNLX
3675
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $84K | ﹤0.01% |
45,000
-81,002
| -64% | -$127K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.